Compare Neurocrine Biosciences Inc (NBIX) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Standard Lithium Ltd — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Standard Lithium Ltd trades at $1.58 (market cap $398.07M). The key difference: Neurocrine Biosciences Inc is far larger — about 36.1× Standard Lithium Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Standard Lithium Ltd for 23 Days on average.
| NBIX | SLI | |
|---|---|---|
Market Cap | $14.36B | $398.07M |
Volume | 1,237,180 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $5.65 |
52-Week Low | $123.10 | $1.58 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $14.37B | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Standard Lithium (SLI) trades at $1.61, down 2.42% on the day, with mixed signals from technical indicators showing bearish moving averages but oversold RSI readings. The company remains pre-revenue with negative profitability metrics (ROE -15.55%, ROA -14.17%) but has shown improving quarterly EPS performance, beating expectations in recent quarters. Recent developments include progress toward a final investment decision for the South West Arkansas lithium project and new customer offtake agreements.
The investment case hinges on successful project execution, with analyst consensus strongly bullish (100% buy ratings) and a $3.83 price target representing 138% upside. Key risks include the pre-revenue status, negative cash flow from operations, and project timeline execution. The stock offers high-risk, high-reward exposure to lithium development with significant government and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
